Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016
Published Jul 20, 2016
72 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016, provides in depth analysis on Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Focal Adhesion Kinase (FAK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
- The report reviews Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic

  
Source:
Document ID
GMDHC0397TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Overview71
Therapeutics Development84
  Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Stage of Development81
  Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Therapy Area91
  Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Indication102
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Companies143
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Universities/Institutes172
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Therapeutics Assessment196
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action202
  Assessment by Route of Administration222
  Assessment by Molecule Type241
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Companies Involved in Therapeutics Development256
  Asana BioSciences, LLC251
  Boehringer Ingelheim GmbH261
  GlaxoSmithKline Plc271
  Takeda Pharmaceutical Company Limited281
  Teva Pharmaceutical Industries Ltd.291
  Verastem, Inc.301
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Drug Profiles3125
  ASN-006 Drug Profile311
  BI-853520 Drug Profile321
  CEP-37440 Drug Profile331
  cilengitide Drug Profile342
  CT-707 Drug Profile361
  CTX-0294886 Drug Profile371
  CTX-0294945 Drug Profile381
  defactinib hydrochloride Drug Profile397
  GSK-2256098 Drug Profile462
  Small Molecule to Inhibit Focal Adhesion Kinase for Solid Tumors Drug Profile481
  Small Molecules to Inhibit FAK for Oncology Drug Profile491
  Small Molecules to Inhibit Focal Adhesion Kinase for Oncology Drug Profile501
  VS-4718 Drug Profile514
  VS-6062 Drug Profile551
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Dormant Projects562
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Discontinued Products581
Focal Adhesion Kinase (FAK or EC 2.7.10.2) Featured News &Press Releases5912
  Jul 05, 2016: Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer591
  May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology601
  May 04, 2016: Verastem Announces the Presentation of Clinical Data at iMig 2016611
  Mar 30, 2016: Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology611
  Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting621
  Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting631
  Jan 21, 2016: Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016641
  Jan 06, 2016: Washington University in St. Louis Initiates Clinical Study of Verastem s VS-6063 in Combination with Merck s Pembrolizumab and Gemcitabine in Pancreatic Cancer651
  Sep 28, 2015: Verastem Stops Enrollment Due to Futility in the Command Study of Vs-6063 for the Treatment of Malignant Pleural Mesothelioma661
  Sep 17, 2015: Verastem Announces Presentation On VS-6063 at ESMO/ECCO 2015661
  Sep 10, 2015: Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer671
  Aug 26, 2015: Verastem to Present Data at the 16th World Conference on Lung Cancer681
  Dec 11, 2014: Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium691
  Dec 04, 2014: Verastem to Present Data on VS-6063 at the 2014 San Antonio Breast Cancer Symposium701
  Dec 04, 2014: Verastem to Present Data on VS-4718 at the 2014 San Antonio Breast Cancer Symposium701
Appendix712
  Methodology711
  Coverage711
  Secondary Research711
  Primary Research711
  Expert Panel Validation711
  Contact Us711
  Disclaimer721

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Focal-Adhesion-Kinase-FAK-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16279>
  
APA:
Global Markets Direct - Market Research. (2016). Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Focal-Adhesion-Kinase-FAK-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16279>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.